Cardiolynx Receives Patent on Improved Angina Pectoris Drug

24-Sep-2012 - Switzerland

Cardiolynx Ltd., specializing in the development of improved cardio-metabolic therapies, announced that the European Patent Office (EPO) has granted a patent covering a new chemical entity, CLC-1280, developed using Cardiolynx' nitric oxide technology. CLC-1280 is based on an established late lifecycle product and is being developed for treating hypertensive patients with angina pectoris.

The Cardiolynx technology employs specific vasodilating chemical linkers as grafts onto or in combination with established cardiovascular drugs resulting in a dual mode of action: the original mode of action of the established product plus the synergistic vasodilative mode.

Dr. Dirk Sartor, CEO of Cardiolynx, commented: "CLC-1280 is active in preclinical models of vasodilatation and has the potential to reduce blood pressure and prevent or reduce angina pectoris thus improving the standard care of this chronic and debilitating condition. The new patent strengthens Cardiolynx's intellectual property portfolio which includes four patent families with pending applications worldwide."

Original publication

Knorr M et al.: "Characterization of new organic nitrate hybrid drugs covalently bound to valsartan and cilostazol."; Pharmacology 2012; 90: 193-204.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances